Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 11Stomach Neoplasms 6Neoplasms 5Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myositis 2Lung Neoplasms 2Cholangiocarcinoma 2Vascular Complications 1Sjogren's Syndrome 1Scleroderma, Systemic 1Sarcopenia 1Recurrence 1Rectal Neoplasms 1Plaque, Atherosclerotic 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Melanoma 1Lupus Erythematosus, Systemic 1Lung Diseases, Interstitial 1Liver Neoplasms 1Influenza, Human 1Immune-Related Adverse Events 1Hypersensitivity 1

Interventions

methyl hydroxyethyl cellulose 1Walking 1Injections, Intra-Articular 1Infliximab 1Immune Checkpoint Inhibitors 1Etanercept 1Cari-D-Tect 1Arthroplasty, Replacement, Shoulder 1Arthroplasty, Replacement, Elbow 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Arthritis × Immune Checkpoint Inhibitors × Clear all
NCT03492242 2019-09-26

CHIMeRA

Groupe Hospitalier Pitie-Salpetriere

Completed
1,000 enrolled

Arthritis, Autoimmune Diseases, Endocrine System Diseases, Eye Diseases, Heart Diseases, Myositis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡